Guideline Updated for Managing Hyperbilirubinemia in Newborns
All families should receive written and verbal education about neonatal jaundice before discharge
Hematologic Disorders
July 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Rebinyn Approval for Hemophilia B Expanded to Include Routine Prophylaxis
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life.
Bifunctional Biologic Gets Orphan Drug Status for Paroxysmal Nocturnal Hemoglobinuria
KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system.
June 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Mosunetuzumab Gets Priority Review for Advanced Follicular Lymphoma
Mosunetuzumab is a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
ProvayBlue Now Available in New Single-Dose Vials for Methemoglobinemia
The new ProvayBlue presentation is supplied in a box of five 10mL single-dose vials; each vial contains 50mg of methylene blue.
Azathioprine Discontinuation Up for Patients With CC Genotype
Patients with rs2814778-CC also have lower last leukocyte count and lower dosing; findings persist after adjustment for race
Novel 12-LOX Inhibitor Fast Tracked for Heparin-Induced Thrombocytopenia
VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway.
